On 28 July 2015, orphan designation (EU/3/15/1531) was granted by the European Commission to Newron Pharmaceuticals SpA, Italy, for sarizotan hydrochloride for the treatment of Rett syndrome.
|Disease / condition||
Treatment of Rett syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.